Search results for: 'learning and development'

Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence ...

As clinical pipelines globally witness a surge in novel complex therapies, the clinical trial industry demands new tools in predictive analytics to improve trial design, planning, and execution. Artificial intelligence is gaining large-scale recognition as support for decentralized trial designs, thus enabling patient-centric clinical trial designs...

A major challenge in drug discovery is the limited number of gene targets that can be targeted for the development of a drug molecule. Only close to 400 genes are proven targets for US FDA-approved drugs. 80% of human genes are unexplored as targets, and some are considered undruggable. The identification and the selection of novel drug targets (p...

Pharmaceutical companies spend billions of dollars in drug development because of expensive and time-consuming clinical trials, with a meager success rate. Frequent clinical visits, manual data processing, and a lack of consistent data on the effectiveness of the investigation of medical products contribute to their low success rate. Digital bio...

Digitalization of the entire value chain will drive next-generation biomanufacturing. The industry is all set to move away from the traditional pen-and-paper-based process to a more advanced, digitized, track-and-trace process that is aligned toward Industry 4.0. Digital tools applied across processes, monitoring, analytics, and operations have acc...

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treat...

This research services provides an overview of the global CAD in breast cancer screening market and a 5-year forecast from 2021 to 2026. The market will grow from $118.0 million in 2021 to $165.7 million in 2026, increasing at a compound annual growth rate (CAGR) of 7.0%. The mammo-CAD and ultrasound-CAD segments will grow at the highest rates due ...

26 Sep 2022  |  Global  |  Market Research

Global Remote Patient Monitoring Growth Opportunities

Interoperability and AI Development will Ensure Future Growth Potential

Infographics

×

Remote patient monitoring is a vital part of patient care, particularly in the treatment of chronic medical conditions, such as diabetes, hypertension, and epilepsy. Technological advances in the RPM space are significant. More reliable connectivity, device interoperability, and smaller, more accurate devices that measure multiple biometrics have m...

31 May 2022  |  North America  |  Market Research

Global RNA Therapeutics Growth Opportunities

Future Growth Potential Driven by Co-Development Programs and Robust Clinical Trials for Diverse Disease Areas

Infographics

×

Scientific advancements in nucleic acid-based therapies have significantly impacted the global biopharmaceutical industry. The ribonucleic acid (RNA) therapeutics market is expected to witness remarkable clinical progress as therapies target “undruggable” pathways. Technologically advanced platforms are integrated into RNA therapeutics bioprocessin...